Do analysts prefer EXOZ or ABEO?

Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 247.99%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is EXOZ or ABEO more profitable?

Abeona Therapeutics' return on equity of -53.98% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Abeona Therapeutics N/A -53.98% -38.52%

Do analysts recommend IMRX or EXOZ?

Immuneering currently has a consensus price target of $16.50, indicating a potential upside of 286.42%. Given Immuneering's stronger consensus rating and higher probable upside, research analysts plainly believe Immuneering is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IMRX or EXOZ more profitable?

Immuneering's return on equity of -31.93% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% eXoZymes N/A -220.63% -141.26%

Do analysts recommend SLN or EXOZ?

Silence Therapeutics currently has a consensus target price of $55.00, indicating a potential upside of 791.41%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BCYC or EXOZ?

Bicycle Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 233.33%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer RZLT or EXOZ?

Rezolute currently has a consensus target price of $8.75, indicating a potential upside of 105.88%. Given Rezolute's stronger consensus rating and higher probable upside, equities analysts plainly believe Rezolute is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, RZLT or EXOZ?

eXoZymes has higher revenue and earnings than Rezolute. eXoZymes is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A eXoZymes $70K 1,101.79 -$9.16M -$1.14 N/A

Is RZLT or EXOZ more profitable?

Rezolute's return on equity of -58.82% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% eXoZymes N/A -220.63% -141.26%

eXoZymes (EXOZ) Competitors

$9.10 -0.26 (-2.73%)

Closing price 06/5/2026 03:59 PM Eastern

Extended Trading

$9.20 +0.11 (+1.21%)

As of 06/5/2026 07:53 PM Eastern

Compare

EXOZ vs. ABEO, IMRX, SLN, BCYC, and RZLT

Should you buy eXoZymes stock or one of its competitors? MarketBeat compares eXoZymes with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with eXoZymes include Abeona Therapeutics (ABEO), Immuneering (IMRX), Silence Therapeutics (SLN), Bicycle Therapeutics (BCYC), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry.

How does eXoZymes compare to Abeona Therapeutics?

eXoZymes (NASDAQ:EXOZ) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

eXoZymes has a beta of 2.65, indicating that its stock price is 165% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

80.6% of Abeona Therapeutics shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Abeona Therapeutics' return on equity of -53.98% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Abeona Therapeutics has higher revenue and earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	1,101.79	-$9.16M	-$1.14	N/A
Abeona Therapeutics	$5.82M	53.46	$71.18M	$0.97	5.63

Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 247.99%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Abeona Therapeutics had 3 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Abeona Therapeutics and 0 mentions for eXoZymes. Abeona Therapeutics' average media sentiment score of 0.46 beat eXoZymes' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
eXoZymes	Neutral
Abeona Therapeutics	Neutral

Summary

Abeona Therapeutics beats eXoZymes on 12 of the 15 factors compared between the two stocks.

How does eXoZymes compare to Immuneering?

Immuneering (NASDAQ:IMRX) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Immuneering's return on equity of -31.93% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
eXoZymes	N/A	-220.63%	-141.26%

eXoZymes has higher revenue and earnings than Immuneering. eXoZymes is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
eXoZymes	$70K	1,101.79	-$9.16M	-$1.14	N/A

Immuneering has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.65, meaning that its share price is 165% more volatile than the broader market.

In the previous week, Immuneering had 5 more articles in the media than eXoZymes. MarketBeat recorded 5 mentions for Immuneering and 0 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.00 beat Immuneering's score of -0.30 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Immuneering	Neutral
eXoZymes	Neutral

Immuneering currently has a consensus price target of $16.50, indicating a potential upside of 286.42%. Given Immuneering's stronger consensus rating and higher probable upside, research analysts plainly believe Immuneering is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

67.7% of Immuneering shares are held by institutional investors. 22.9% of Immuneering shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Immuneering beats eXoZymes on 9 of the 15 factors compared between the two stocks.

How does eXoZymes compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

98.7% of Silence Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 72.4% of eXoZymes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Silence Therapeutics currently has a consensus target price of $55.00, indicating a potential upside of 791.41%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

eXoZymes has lower revenue, but higher earnings than Silence Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	520.48	-$88.61M	-$1.59	N/A
eXoZymes	$70K	1,101.79	-$9.16M	-$1.14	N/A

eXoZymes has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -105.34% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
eXoZymes	N/A	-220.63%	-141.26%

Silence Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.65, meaning that its share price is 165% more volatile than the broader market.

In the previous week, Silence Therapeutics' average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
eXoZymes	Neutral

Summary

Silence Therapeutics beats eXoZymes on 9 of the 15 factors compared between the two stocks.

How does eXoZymes compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

eXoZymes has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
eXoZymes	N/A	-220.63%	-141.26%

Bicycle Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 233.33%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Bicycle Therapeutics had 3 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Bicycle Therapeutics and 0 mentions for eXoZymes. Bicycle Therapeutics' average media sentiment score of 0.33 beat eXoZymes' score of 0.00 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
eXoZymes	Neutral

86.2% of Bicycle Therapeutics shares are held by institutional investors. 22.9% of Bicycle Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

eXoZymes has lower revenue, but higher earnings than Bicycle Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.02	-$218.96M	-$3.15	N/A
eXoZymes	$70K	1,101.79	-$9.16M	-$1.14	N/A

Bicycle Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.65, indicating that its stock price is 165% more volatile than the broader market.

Summary

Bicycle Therapeutics beats eXoZymes on 10 of the 16 factors compared between the two stocks.

How does eXoZymes compare to Rezolute?

Rezolute (NASDAQ:RZLT) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Rezolute has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.65, meaning that its stock price is 165% more volatile than the broader market.

In the previous week, Rezolute had 14 more articles in the media than eXoZymes. MarketBeat recorded 14 mentions for Rezolute and 0 mentions for eXoZymes. Rezolute's average media sentiment score of 0.47 beat eXoZymes' score of 0.00 indicating that Rezolute is being referred to more favorably in the media.

Company	Overall Sentiment
Rezolute	Neutral
eXoZymes	Neutral

Rezolute currently has a consensus target price of $8.75, indicating a potential upside of 105.88%. Given Rezolute's stronger consensus rating and higher probable upside, equities analysts plainly believe Rezolute is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rezolute's return on equity of -58.82% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
eXoZymes	N/A	-220.63%	-141.26%

eXoZymes has higher revenue and earnings than Rezolute. eXoZymes is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
eXoZymes	$70K	1,101.79	-$9.16M	-$1.14	N/A

Summary

Rezolute beats eXoZymes on 10 of the 14 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXOZ vs. The Competition

Export

Metric	eXoZymes	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$79.19M	$3.34B	$6.68B	$11.99B
Dividend Yield	N/A	2.31%	2.67%	5.55%
P/E Ratio	-7.98	19.02	24.06	23.63
Price / Sales	1,101.79	300.07	516.28	112.14
Price / Cash	N/A	116.33	42.23	54.60
Price / Book	22.74	6.51	9.73	6.35
Net Income	-$9.16M	$24.19M	$3.57B	$337.59M
7 Day Performance	-5.06%	-6.96%	-1.28%	-2.52%
1 Month Performance	-9.05%	-2.80%	1.38%	-0.03%
1 Year Performance	-32.33%	36.80%	23.93%	25.34%

eXoZymes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXOZ eXoZymes	0.3218 of 5 stars	$9.10 -2.7%	N/A	-32.3%	$79.19M	$70K	N/A	29
ABEO Abeona Therapeutics	3.3469 of 5 stars	$5.78 flat	$19.00 +228.7%	-19.0%	$329.43M	$14.54M	5.96	90
IMRX Immuneering	1.9983 of 5 stars	$5.77 +14.0%	$16.50 +186.0%	+100.5%	$327.37M	N/A	N/A	60	High Trading Volume
SLN Silence Therapeutics	2.381 of 5 stars	$6.90 +0.6%	$55.00 +697.1%	+13.4%	$325.92M	$839K	N/A	100
BCYC Bicycle Therapeutics	4.0121 of 5 stars	$4.69 +0.4%	$14.00 +198.5%	-50.9%	$325.53M	$63.50M	N/A	240	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXOZ) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

eXoZymes (EXOZ) Competitors

EXOZ vs. ABEO, IMRX, SLN, BCYC, and RZLT

How does eXoZymes compare to Abeona Therapeutics?

Summary

How does eXoZymes compare to Immuneering?

Summary

How does eXoZymes compare to Silence Therapeutics?

Summary

How does eXoZymes compare to Bicycle Therapeutics?

Summary

How does eXoZymes compare to Rezolute?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

eXoZymes (EXOZ) Competitors

EXOZ vs. ABEO, IMRX, SLN, BCYC, and RZLT

How does eXoZymes compare to Abeona Therapeutics?

Which has more volatility & risk, EXOZ or ABEO?

Do insiders & institutionals have more ownership in EXOZ or ABEO?

Is EXOZ or ABEO more profitable?

Which has stronger earnings and valuation, EXOZ or ABEO?

Do analysts prefer EXOZ or ABEO?

Does the media prefer EXOZ or ABEO?

Summary

How does eXoZymes compare to Immuneering?

Is IMRX or EXOZ more profitable?

Which has preferable earnings & valuation, IMRX or EXOZ?

Which has more volatility & risk, IMRX or EXOZ?

Does the media favor IMRX or EXOZ?

Do analysts recommend IMRX or EXOZ?

Do insiders and institutionals believe in IMRX or EXOZ?

Summary

How does eXoZymes compare to Silence Therapeutics?

Do institutionals & insiders believe in SLN or EXOZ?

Do analysts recommend SLN or EXOZ?

Which has stronger valuation & earnings, SLN or EXOZ?

Is SLN or EXOZ more profitable?

Which has more volatility and risk, SLN or EXOZ?

Does the media favor SLN or EXOZ?

Summary

How does eXoZymes compare to Bicycle Therapeutics?

Is BCYC or EXOZ more profitable?

Do analysts rate BCYC or EXOZ?

Does the media favor BCYC or EXOZ?

Do institutionals and insiders believe in BCYC or EXOZ?

Which has stronger earnings & valuation, BCYC or EXOZ?

Which has more risk and volatility, BCYC or EXOZ?

Summary

How does eXoZymes compare to Rezolute?

Do institutionals & insiders believe in RZLT or EXOZ?

Which has more volatility & risk, RZLT or EXOZ?

Does the media favor RZLT or EXOZ?

Do analysts prefer RZLT or EXOZ?

Is RZLT or EXOZ more profitable?

Which has higher earnings & valuation, RZLT or EXOZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools